Clinical trial
Phase II Study of Durvalumab ,Doxorubicin, and Ifosfamide in Pulmonary Sarcomatoid Carcinoma
NCT04224337 is registered in ClinicalTrials.gov with Seoul National University Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase II Study of Durvalumab ,Doxorubicin, and Ifosfamide in Pulmonary Sarcomatoid Carcinoma
- Lead sponsor
- Seoul National University Hospital
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- June 11, 2020
- Completion date
- May 7, 2025
- Enrollment
- 16 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.